WELL Health
TECHNOLOGIES CORP

Q2-2026 Earnings Presentation

August 6, 2026

Disclaimer

This presentation contains forward-looking statements and forward-looking information within the meaning of applicable securities laws. These statements relate to future events or future performance. All statements other than statements of historical fact may be forward-looking statements or information. Forward-looking statements and information are often, but not always, identified by the use of words such as "appear", "seek", "anticipate", "plan", "continue", "estimate", approximate", expect", "may", "will", "project", "predict", "potential", "targeting", "intend", "could", "might", "should", "believe", "would" and similar expressions. Forward-looking statements and information are provided for the purpose of providing information about the current expectations and plans of the management of the Company relating to the future. Readers are cautioned that reliance on such statements and information may not be appropriate for other purposes, such as making investment decisions. Since forward-looking statements and information address future events and conditions, by their very nature they involve inherent risks and uncertainties.

Actual results could differ materially from those currently anticipated due to a number of factors and risks. These include, but are not limited to, the risks associated with: primary healthcare sector in general; competition; that future results may vary from historical results; the availability and effective integration and operation of management information systems and other technologies; ability to mitigate against cyber security risks; ability to access sufficient capital from internal and external sources; changes in legislation, including but not limited to tax laws; and government regulations. Accordingly, readers should not place undue reliance on the forward- looking statements, timelines and information contained in this presentation. Readers are cautioned that the foregoing list of factors is not exhaustive.

The forward-looking statements and information contained in this presentation are made as of the date hereof and no undertaking is given to update publicly or revise any forward-looking statements or information, whether as a result of new information, future events, or otherwise, unless so required by applicable securities laws or the TSX Exchange. The forward-looking statements or information contained in this presentation are expressly qualified by this cautionary statement. The TSX Exchange has in no way passed upon the merits of the proposed transaction and has neither approved nor disapproved of the contents of this presentation.

Execution Across Every Pillar of Our Strategy

Clinic transactions with corresponding revenue and billable provider metrics

New 2026 Guidance[1]:

$1.58-1.65B Revenue
$185-195M Adj. EBITDA

HIGHLIGHTS:

1. **WELL Canada achieved $100M Adjusted EBITDA target**
2. **Completed $150M bond offering**
3. **WELLSTAR completed $50M financing**
4. **Strategic acquisitions of OID and UnionMD**

ONTARIO IMAGING Diagnostics

Union MD

(1) This guidance includes the effect of $17.6 million in deferred revenue from WELL's majority owned subsidiary, Circle Medical expected to be recognized in 2026. For more information regarding this impact, please refer to WELL's Q2-26 MD&A.

WELL Q2-2026 Key Financial Highlights[1]

Q2 Revenue **$400.4M** +12% Y/Y	Q2 Adj. EBITDA **$48.1M** -3% Y/Y	Q2 Adj. Sh. EBITDA **$35.3M** -6% Y/Y
Q2 Normalized Revenue **$395.6M** +14% Y/Y	Q2 Normalized Adj. EBITDA **$43.3M** +8% Y/Y	Q2 Normalized Adj. EBITDA **$32.0M** +4% Y/Y

1) *All figures include $4.8 million in Circle Medical revenue deferral impacts for Q2-2026 and $9.7 million for the comparable prior-year period.*

WELL Q2-2026 Key Financial Highlights[1]

Q2 Adj. Gross Profit	Q2 Adj. Gross Margin	Q2 Adj. Net Income
$178.4M	44.6%	$11.6M
+12% Y/Y	+10 bps Y/Y	-55% Y/Y

Q2 Normalized Adj. Gross Profit	Q2 Normalized Adj. Gross Margin	Q2 Normalized Adj. Net Income
$173.6M	43.9%	$9.2M
+17% Y/Y	+90 bps Y/Y	-56% Y/Y

1) *All figures include $4.8 million in Circle Medical revenue deferral impacts for Q2-2026 and $9.7 million for the comparable prior-year period.*

WELL June-2026 – Monthly Performance Exiting Quarter[1]

June 2026 Revenue	June 2026 Adj. EBITDA	June 2026 Adj. Sh. EBITDA
$144.3M	$17.6M	$13.3M
+24% Y/Y	+12% Y/Y	+28% Y/Y

June 2026 Normalized Revenue	June 2026 Normalized Adj. EBITDA	June 2026 Normalized Adj. Sh. EBITDA
$144.2M	$17.6M	$13.2M
+28% Y/Y	+43% Y/Y	+66% Y/Y

1) *All figures include $74 thousand in Circle Medical revenue deferral impacts for June 2026 and $3.4 million for the comparable prior-year period.*

WELL Q2-2026 Operational Highlights[1]

5,000+
Providers in WELL's Clinic Network
(1,500+ physicians in Canada)

2.0M+
Patient visits (CAN + US)
+19% YoY
(+5% organic)

1.4M
CAN patient visits
in Q2-2026
(5.6M annualized run-rate)

45,000+
Unique Providers supported by WELLSTAR's Technology

3.1 M+
Total Care Interactions[2]
+21% YoY
(+11% organic)

+28%
YoY CAN patient visit growth

1) *All figures exclude HEALWELL AI*
2) *Definition of Care Interactions = patient visits plus technology interactions*

Making a Positive Impact on Canadian Healthcare

2-Week

Wait Time

WELL Cardiologists vs. 15.3-week industry average[1]

80%

Reduction in No-Shows

at WELL Clinics due to tech enablement

85K+

WELL Trust Consents

collected as of June 30, 2026

1) Fraser Institute, Waiting Your Turn: Wait Times for Health Care in Canada, 2025 Report, published on December 9, 2025.

Strengthening Our Executive Leadership Team

Four strategic appointments across operations, legal, technology and public sector strengthen WELL's leadership bench

Derek Clark

Chief Operating Officer

Operational execution, scalability and enterprise performance across WELL's platform

Loreto Grimaldi

Chief Legal Officer

Legal, compliance, governance, risk management and M&A strategy

Kaytek Przybylski

Chief Digital & Information Officer

Enterprise technology, digital transformation, data, AI and cybersecurity

Dr. Andrew Bond

Chief Health Officer & Head of Public Sector

Clinical governance, government relations and WELL's public sector growth strategy

Six Defining Pressures the Canadian Healthcare System is Facing Today

1 **Access**

6.5M Canadians have no family doctor.

2 **Provider burnout**

47% of physicians report burnout.

3 **Chronic disease & acute capacity**

20% of hospital budgets ($2.5B) tied to avoidable acute-care use.[1]

4 **Fiscal ceiling**

Health spending is outpacing budget growth in every jurisdiction.

5 **Aging population**

Seniors are the fastest-growing share of every provincial population.

6 **Data fragmentation**

70% of health data still isn't shared across care settings.

1) *Basu (2025) Hosp. Top.*

WELL's Vision -> To be the Operating System Underpinning Outpatient Healthcare at Scale for a More Modern Canadian Healthcare System

Delivery

WELL's Clinics, WELL Diagnostics & virtual care deliver access to excellent care and generate real-world data

↔

Technology

EMR, billing & connectivity software run the care and systems every day

↔

Intelligence

AI & analytics turn Canada's largest primary care dataset into insight and tools for better decisions

Clinics that deliver care. Technology that runs it. AI that makes it smarter.

OneWELL

One integrated platform to address Canada's healthcare needs.

WELL Health

01
Delivering connected care

WELL Health | CLINIC NETWORK

02
Tech-enabling Providers

WELLSTAR

03
Population Health & AI

HEALWELL AI

Successful Inaugural Bond Offering

Extends debt maturity to 2031 and strengthens the balance sheet to support continued growth in Canada.

$150M
Senior Unsecured

6.875%
Coupon (per annum)

2031
Maturity (5-year Notes)

July 15, 2026
Closed

USE OF PROCEEDS

- ✓ Repay convertible debentures due Dec. 2026
- ✓ General corporate purposes

TRANSACTION HIGHLIGHTS

- ✓ WELL's inaugural senior unsecured notes offering
- ✓ Extends debt maturity profile to 2031
- ✓ Ranks equally with other senior unsecured debt

WELL Canada Experiencing Consistent Growth & Profitability





1) *WELL Canada includes Canadian Clinics, WELLSTAR and CYBERWELL. Revenue includes Intercompany revenue.*
2) *One time reimbursement lift refers to Canadian Patient Services reimbursement revenue received in Q2-2025 for services provided in prior quarters*

WELL Health TECHNOLOGIES CORP

WELL Canadian Clinics Financial Performance

WELL Canadian Clinics Annual Revenue Growth

(C$ in 000s)



WELL Canadian Clinics Annual Adj. EBITDA Growth

(C$ in 000s)



WELL Canadian Clinics Count[1]



WELL Health TECHNOLOGIES CORP

WELL Providers Are Seeing More Patients

WELL Canadian Clinics Patient Visits



Billable Providers in WELL's Canadian Clinics Network



Patient Visits / Billable Provider[1]



1) Excludes acquisitions completed during the quarter, as patient visit totals for these acquisitions are not yet fully reflective of a complete quarter of operations. Including acquisitions, Including acquisitions, Patient Visits / Billable Provider would be 557.

WELL Health TECHNOLOGIES CORP

Canadian Clinic Recent M&A Activity

Clinic transactions with corresponding revenue and billable provider metrics

Q3-2025	Q4-2025	Q1-2026[1]	Q2-2026
+5 Clinics 5 transactions	**+25 Clinics** 7 transactions	**+3 Clinics** 3 transactions	**+23 Clinics** 3 transactions
+$27.5M Annual Revenue	**+$45.6M** Annual Revenue	**+$34.0M** Annual Revenue	**+$67.8M** Annual Revenue
+81 Providers Total Canadian Clinics	**+109 Providers** Total Canadian Clinics	**+77 Providers** Total Canadian Clinics	**+117 Providers** Total Canadian Clinics

1) *Q1-2026 M&A Activity includes the e-consult acquisition closed on February 1, 2026*

WELL Health TECHNOLOGIES CORP

WELL Canada M&A Pipeline

WELL continues to execute on a robust pipeline, driving growth and sustaining strong operational momentum.

WELL Canada
Total Pipeline[1]

WELL Canada
Under LOI or Advanced Stage[2]

1) *WELL Canada includes Canadian Clinics, WELLSTAR, and CYBERWELL*
2) *The Total WELL Pipeline includes potential deals that are under LOI and in the pre-LOI stage for WELL Canada*

WELLSTAR: TSXV Listing & $50M Concurrent Financing

Concurrent Financing closed July 30, 2026 ahead of WELLSTAR's planned standalone TSXV listing

$50M	~$95M	Rule of 40+	$162M
Gross Proceeds	Expected 2026 Revenue	Growth + Profitability	Total Raised Last 19 Months[1]

TRANSACTION HIGHLIGHTS

- ✓ The $50M Concurrent Financing closed July 30, 2026 — C$36.2M via treasury subscription receipts and C$13.8M via a secondary offering by an existing shareholder
- ✓ Anchored by a large Canadian bank-owned asset manager, new institutional investors, and existing shareholders.
- ✓ WELL will remain a majority, long-term controlling shareholder and growing customer of WELLSTAR following the listing.
- ✓ Use of proceeds include strategic acquisitions, AI-driven product innovation, organic growth initiatives, and general corporate purposes

1) *Gross Proceeds of $162 million includes $148.2 million in Treasury offering and $13.8 million in secondary offering*

WELLSTAR: Continued Financial Out-performance







1) WELLSTAR's revenue in the chart includes intercompany revenues.
2) WELLSTAR's Adj. EBITDA excludes Shared Services expenses
3) Comparative periods have been restated to include expenses previously covered by the parent company, providing comparability with the current period.
4) Pubco Costs refers to expenses associated with WELLSTAR's spinout, including audit and board fees.

WELL Health TECHNOLOGIES CORP

Strategic Alternatives Processes for US Assets

wisp

CRH Medical
CORPORATION
A WELL Health Company

Circle Medical

Q2-2026 Financial Highlights: Revenue

(C$ in 000,000s)



1) *WELL Canada includes Canadian Clinics, WELLSTAR and CYBERWELL*
2) *Others includes Corporate, WELL Research, and HEALWELL*
3) *One time reimbursement lift refers to Canadian Patient Services reimbursement revenue received in Q2-2025 for services provided in prior quarters*

WELL Health TECHNOLOGIES CORP

Q2-2026 Financial Highlights: Adjusted EBITDA

(C$ in 000,000s)



1) *WELL Canada includes Canadian Clinics, WELLSTAR and CYBERWELL*
2) *Others includes Corporate, WELL Research, and HEALWELL*
3) *One time reimbursement lift refers to Canadian Patient Services reimbursement revenue received in Q2-2025 for services provided in prior quarters*

WELL Health TECHNOLOGIES CORP

Q2-2026 Financial Highlights: Adjusted Net Income[2]



(1) Non-operating Items include other items such as Depreciation, FX gain/loss, Interest Income, Gain on disposal of assets and investments, and NCI included in net income

(2) Adjusted Net Income is net income (loss) adjusted to remove the impact of non-cash items, non-recurring or non-operational gains and losses, and revenue timing differences that do not reflect the Company's underlying operating performance.

(3) One time reimbursement lift refers to Canadian Patient Services reimbursement revenue received in Q2-2025 for services provided in prior quarters

(4) Legal & other costs includes litigation, settlement, and defense costs net of insurance recovery

WELL Health TECHNOLOGIES CORP

Q2-2026 Financial Highlights: Adjusted FCFA2S

Adjusted Free Cashflow Attributable to Shareholders

(C$ in 000,000s)



(1) *Values refer to changes in Shareholder Adjusted EBITDA from Q2-25 to Q2-26*

WELL Health TECHNOLOGIES CORP

Upgraded Outlook

Disciplined Capital Allocation Program Driving Scale

2026 Guidance[1]:
$1.58-1.65B Revenue
$185-195M Adj. EBITDA

WELL Canada[2]
>$1 Billion Revenue
run-rate by end of 2028

WELLSTAR expected to begin trading on TSX Venture Exchange in September

WELL Canadian Clinics
>$100M Adj. EBITDA
run-rate by end of 2026

1) *This guidance includes the effect of $17.6 million in deferred revenue from WELL's majority owned subsidiary, Circle Medical expected to be recognized in 2026. For more information regarding this impact, please refer to WELL's Q2-26 MD&A.*
2) *WELL Canada includes Canadian Clinics, WELLSTAR, and CYBERWELL. Targets are Inclusive of acquisitions.*

Contact

Hamed Shahbazi
CEO, Chairman & Founder
hamed@well.company

Eva Fong
Chief Financial Officer
eva.fong@well.company

Pardeep Sangha
Investor Relations
investor@well.company

www.well.company

Vancouver, BC
Canada

WELL Health
TECHNOLOGIES CORP